Dihydroartemisinin alleviates lung injury in rat models with chronic obstructive pulmonary disease(COPD)
QIN Yuchun1, KUANG Xiangdong1*, CAI Linzai1, XIE Jingchen1, CHEN Shan2
1. Department of Respiratory and Critical Care Medicine, Hainan West Central Hospital, Danzhou 571700; 2. Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Hainan Medical College, Haikou 570311,China
Pulito C, Strano S, Blandino G. Dihydroartemisinin: from malaria to the treatment of relapsing head and neck cancers[J]. Ann Transl Med, 2020, 8:612-615.
Yang DX, Qiu J, Zhou HH, et al. Dihydroartemisinin alleviates oxidative stress in bleomycin-induced pulmonary fibrosis[J]. Life Sci, 2018, 205:176-183.
[5]
Huang H, Huang X, Zeng K, et al. Interleukin-6 is a strong predictor of the frequency of COPD exacerbation within 1 year[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16:2945-2951.
[6]
Chen D, Li Z, Bao P, et al. Nrf2 deficiency aggravates Angiotensin II-induced cardiac injury by increasing hypertrophy and enhancing IL-6/STAT3-dependent inflamma-tion[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865:1253-1264.